Fingerprint
Dive into the research topics of 'Correction to: N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial (Annals of Oncology (2010) 21(8) (1729–1730), (S0923753419353116), (10.1093/annonc/mdp328))'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically